DCGI approves anti-Covid drug developed by DRDO

Credit: pixabay.com

The oral drug has been developed by Institute of Nuclear Medicine and Allied Sciences, a lab of DRDO, in collaboration with Dr Reddy’s Laboratories, Hyderabad.

The Drugs Controller General of India (DCGI) cleared the drug after clinical trial (phase-III) results showed that a molecule present in the drug helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence. A higher proportion of patients treated with the drug showed tested negative for Covid in RT-PCR tests.

Current Issue

NEWSLETTER